Mercado mundial de hidroxicloroquina: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de hidroxicloroquina

Según la OMS, en 2018 se notificaron más de 228 millones de casos de malaria en todo el mundo y hubo 405.000 muertes relacionadas con la malaria. El grupo de edad más vulnerable a la malaria son los niños menores de cinco años; en 2018, representaron el 67% (o 272.000) de todas las muertes relacionadas con la malaria que se notificaron a nivel mundial. El uso de hidroxicloroquina para prevenir y tratar los ataques agudos de malaria es resultado del aumento de la prevalencia de la malaria. Los parásitos de la malaria Plasmodium ovale (P. ovale), Plasmodium malariae, Plasmodium vivax y las formas vulnerables de P. falciparum han sido combatidos con éxito con hidroxicloroquina.  

Data Bridge Market Research analiza que se espera que el mercado de hidroxicloroquina, que fue de USD 1.270,86 millones en 2022, alcance los USD 3.246,88 millones para 2030, a una CAGR del 12,44% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de canalización, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de hidroxicloroquina  

Market Definition

A chemotherapeutic medication called hydroxychloroquine (HCQ) is primarily used to treat and prevent malaria. It works against erythrocytic malarial parasite types and is often administered orally as a tablet. Additionally, it is used to treat diseases such as systemic lupus erythematosus, rheumatoid arthritis, Q fever, and porphyria cutanea tarda (PCT), and it is undergoing clinical trials as a treatment for the quickly spreading COVID-19 disease. It is immunosuppressive, anti-autophagy, and antimalarial because it inhibits immune functions and manifests antigens and cytokines in the body.

Hydroxychloroquine Market Dynamics

Drivers

• Rise in the prevalence of malaria in low-income countries will bolster the market growth

The increase in malaria prevalence in low-income countries is expected to boost the market's growth rate. A potentially fatal infectious disease called malaria is conveyed by female Anopheles mosquitoes and is brought on by the Plasmodium parasite. Climate change is facilitating the malaria epidemic's expansion and enhancing mosquito-borne diseases' viability. In 2019, there were around 229 million malaria cases and 409,000 fatalities worldwide, according to the WHO. Tropical regions, including Africa, Asia, Central America, and South America, have been most affected by malaria. Additionally, Africa, Southeast Asia, the Eastern Mediterranean, and the Western Pacific are the regions where malaria is most prevalent.

• Rising cases of COVID will drive the market growth

On April 8th, 2020, there were 73,639 confirmed cases and 6,695 fatalities. The government is looking for efficient solutions for the patients' treatment as a result of the COVID-19 outbreaks. The countries are searching for choices that are easily accessible for the treatment of COVID-19 because no medications have been approved for the disease. The majority of countries, including the US, Brazil, Spain, Bahrain, Germany, Nepal, Bhutan, and Bangladesh, have moved their focus to hydroxychloroquine due to its proven antiviral action, which may help to activate the immune system. This in turn is influencing the increased use of hydroxychloroquine medications.

Opportunities

• Rising penetration of generic drugs will act as a opportunity

Increased demand for new hydroxychloroquine and expanding generic drug penetration are anticipated to impact the market positively. For instance, in March 2020, Novartis International AG started delivering 30 million doses of hydroxychloroquine tablets to the U.S. Department of Health and Human Services (HHS) for supervised clinical trials to evaluate the effectiveness of hydroxychloroquine in patients with coronavirus illness (COVID 19). The enhanced government support is also anticipated to impact the market penetration of growing product approval substantially.

Restraints/Challenges

• Side effects associated with hydroxychloroquine

Chloroquine and hydroxychloroquine are known to cause heart rhythm problems, and they might get worse if treatment is combined with drugs that have similar effects on the heart, such as the antibiotic azithromycin. This is according to a study by the European Drugs Agency. Azithromycin, combined with chloroquine or hydroxychloroquine, has been related to serious, and in some cases fatal, heart rhythm problems, especially when used at high doses. This will slow the market's rate of expansion.

This hydroxychloroquine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hydroxychloroquine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Hydroxychloroquine Market

The COVID-19 outbreak has raised the need for medication, which has led to a large growth in the market size. Recently, hydroxychloroquine's efficacy in treating COVID-19-infected patients has been interesting. According to Chinese sources, Chloroquine has been demonstrated to inhibit SARS-CoV-2 in vitro. The medication has been proven to be quite successful in treating COVID-19 patients. It is thought that the coronavirus medication hydroxychloroquine is a potentially effective treatment (for COVID 19). Hydroxychloroquine has been approved for use as an urgent treatment for coronavirus infection by the U.S. Food and Drug Administration (FDA).

Recent Developments

• In February 2022, Accord Healthcare Inc. introduced the additional strengths of hydroxychloroquine sulfate tablets in the United States. The generic version of Plaquenil, hydroxychloroquine, is typically used to treat malaria, lupus, and rheumatoid arthritis. The creation and commercialization of these distinctive capabilities demonstrate Accord's dedication to addressing patients' unmet requirements for accurate dosage of significant medications in the United States. The newly released item completes Accord's earlier 200mg Hydroxychloroquine tablet release.

Global Hydroxychloroquine Market Scope

The hydroxychloroquine market is segmented on the basis of Strength, grade, drug class, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Strength

• 200 mg
• 400 mg
• 800 mg

Grade

• USP Standards Grade
• EP Standards Grade
• Pharmaceutical Standards Grade
• Others

Drug Class

• Antimalarial
• Anti-rheumatic Hydroxychloroquine Drug
• Lupus Suppressant Hydroxychloroquine Drug
• Hydroxychloroquine Drug
• Anti-COVID 19 Hydroxychloroquine Drug

Dosage Forms

• Tablets
• Others

Route of Administration

• Oral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

 Hydroxychloroquine Market Regional Analysis/Insights

The hydroxychloroquine market is analysed and market size insights and trends are provided by country, Strength, grade, drug class, dosage forms, route of administration, end-users and distribution channel as referenced above.

The countries covered in the hydroxychloroquine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

América del Norte dominó el mercado de la hidroxicloroquina debido a la importante industria manufacturera de la región y a la infraestructura sanitaria desarrollada. El elevado gasto en I+D, así como la disponibilidad de trabajadores cualificados, acelerarán aún más la tasa de crecimiento del mercado en esta zona.

Se espera que la región de Asia y el Pacífico crezca a la tasa más alta en el período de pronóstico de 2023 a 2030 debido a las campañas de concientización gubernamentales ampliadas y al aumento de los costos de la atención médica en esta área. Además, la creciente disponibilidad de medicamentos genéricos desacelerará la expansión del mercado en esta área.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.

Análisis del panorama competitivo y de la cuota de mercado de la hidroxicloroquina

El panorama competitivo del mercado de hidroxicloroquina proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento del producto, la amplitud y la variedad del producto, el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de hidroxicloroquina.

Algunos de los principales actores que operan en el mercado de hidroxicloroquina son:

• Actiza Pharmaceutical Private Limited (India)
• AdvaCare Pharma (Estados Unidos)
• Laboratorios Ipca Ltd. (India)
• Bliss GVS Pharma Ltd. (India)
• GeoVax (Estados Unidos)
• Sumaya Biotech (Alemania)
• VLP Therapeutics (Estados Unidos)
• OSIVAX (Francia)
• AJANTA FARMACIA (India)
• Strides Pharma Science Limited (India)
• Mylan NV (Estados Unidos)
• Zydus Cadila (India)
• Cipla Inc. (Estados Unidos)
• Industrias farmacéuticas Sun Ltd. (India)
• Sanofi (Francia)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Amneal Pharmaceuticals LLC. (Estados Unidos)
• Taj Pharmaceuticals Limited (India)
• Lupino (India)
• Novartis AG (Suiza)
• Pfizer Inc. (Estados Unidos)

SKU-53425